GERMANY – Yendou, a Berlin, Germany-based provider of a clinical operations automation platform, raised $1.3m in pre-seed funding.
The round was led by us at b2venture, with support from Heartfelt, Infinite Fund, and several angel investors from the pharmaceutical industry, including Meri Beckwith, co-founder of the new CRO challenger Lindus Health. The company intends to use the funds to expand operations and its development efforts. Led by CEO and co-founder Zina Sarif, and co-founder Patrick Rogg, Yendou provides a clinical operations automation platform to accelerate the operational efficiency of clinical trials. Since its launch in March 2023, the company has rapidly gathered attention and adoption from over 1,200 clinicians in 46 countries. Following this success, Yendou opened its platform to pharmaceutical companies in a closed beta offering. This offering enables pharmaceutical and biotech companies to connect, select, and onboard clinical trial sites for Phase II and Phase III oncology trials seamlessly. 28/02/2024
